NewAmsterdam Pharma Company NV (NAMS)

Currency in USD
25.070
-0.100(-0.40%)
Closed·
24.690-0.380(-1.52%)
·
NAMS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
NAMS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
24.88025.640
52 wk Range
14.06027.290
Key Statistics
Prev. Close
25.17
Open
25.24
Day's Range
24.88-25.64
52 wk Range
14.06-27.29
Volume
1.03M
Average Volume (3m)
855.84K
1-Year Change
52.96%
Book Value / Share
6.93
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NAMS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
40.445
Upside
+61.33%
Members' Sentiments
Bearish
Bullish
ProTips
7 analysts have revised their earnings upwards for the upcoming period
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

NewAmsterdam Pharma Company NV Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NewAmsterdam Pharma Company NV SWOT Analysis


Promising Pipeline
NewAmsterdam Pharma's lead candidate obicetrapib shows potential to become a standard-of-care second-line therapy for cardiovascular disease management
Clinical Milestones
Explore the accelerated timeline for TANDEM study results and the ongoing PREVAIL outcomes study, both crucial for obicetrapib's market prospects
Market Potential
Analysts project U.S. sales exceeding $1.3 billion, with price targets ranging from $36.79 to $52.05, indicating significant upside potential
Competitive Edge
Delve into obicetrapib's unique profile as a CETP inhibitor, potentially offering advantages over existing treatments in efficacy, safety, and convenience
Read full SWOT analysis

Compare NAMS to Peers and Sector

Metrics to compare
NAMS
Peers
Sector
Relationship
P/E Ratio
−17.0x−1.4x−0.5x
PEG Ratio
−0.410.000.00
Price/Book
3.6x2.8x2.6x
Price / LTM Sales
44.1x8.0x3.3x
Upside (Analyst Target)
64.4%263.7%40.3%
Fair Value Upside
Unlock29.6%5.1%Unlock

Analyst Ratings

11 Buy
1 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 40.445
(+61.33% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
-0.1465 / -0.4941
Revenue / Forecast
19.15M / 2.13M
EPS Revisions
Last 90 days

NAMS Income Statement

People Also Watch

185.85
ALAB
-2.54%
20.51
ARWR
+9.21%
10.24
PHAT
-2.20%
45.00
AAPG
+5.98%

FAQ

What Stock Exchange Does NewAmsterdam Pharma Trade On?

NewAmsterdam Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for NewAmsterdam Pharma?

The stock symbol for NewAmsterdam Pharma is "NAMS."

What Is the NewAmsterdam Pharma Market Cap?

As of today, NewAmsterdam Pharma market cap is 2.82B.

What Is NewAmsterdam Pharma's Earnings Per Share (TTM)?

The NewAmsterdam Pharma EPS (TTM) is -1.55.

When Is the Next NewAmsterdam Pharma Earnings Date?

NewAmsterdam Pharma will release its next earnings report on 16 Nov 2025.

From a Technical Analysis Perspective, Is NAMS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has NewAmsterdam Pharma Stock Split?

NewAmsterdam Pharma has split 0 times.

How Many Employees Does NewAmsterdam Pharma Have?

NewAmsterdam Pharma has 68 employees.

What is the current trading status of NewAmsterdam Pharma (NAMS)?

As of 16 Aug 2025, NewAmsterdam Pharma (NAMS) is trading at a price of 25.07, with a previous close of 25.17. The stock has fluctuated within a day range of 24.88 to 25.64, while its 52-week range spans from 14.06 to 27.29.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.